Dendrobium officinale polysaccharide improves PMOS by regulating gut microbiota disorder
Background: Polyglandular metabolic ovarian syndrome (PMOS) is a prevalent endocrine disorder in women, accompanied by reduced fertility, increased miscarriage risk, insulin resistance, obesity, and other metabolic abnormalities. Dendrobium officinale polysaccharide (DOCP) can regulate blood glucose and improve gastrointestinal health; however, its underlying mechanism against PMOS ‑ induced glucose and lipid metabolic disorders remains unclear. This study aimed to explore the ameliorative effects of DOCP on systemic lipid accumulation and chronic inflammation induced by intestinal barrier dysfunction in PMOS mice. Methods: A PMOS mouse model was established via dehydroepiandrosterone injection combined with a high - fat and high - sugar diet for 28 days. Model mice were treated with Dendrobium officinale extract (DOE) or DOCP for 8 weeks, followed by the detection of serum sex hormones, metabolic parameters, tissue pathological damage, hepatic inflammatory factors, and gut microbiota composition. Results: DOCP significantly improved hormonal and metabolic disorders, alleviated pathological injuries in the ovary, colon and liver, and downregulated the expression of IL - 6 and TNF ‑α in hepatic tissue. Furthermore, DOCP remodeled gut microbiota homeostasis, repaired intestinal barrier damage, and reduced systemic lipid accumulation. Conclusion: In conclusion, DOCP ameliorates PMOS ‑ related hormonal and metabolic disturbances by regulating gut microbiota and inhibiting adipose ‑ derived inflammatory responses, indicating its promising clinical application for PMOS treatment.